Paper37569693
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
Wei W and 2 others. Int J Mol Sci, 2023. Cited by 64 papers, by iCite.
Cite this record
ConductScience Library. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. Papers, record 37569693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37569693
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Chimeric Antigen | Major topic |
| Neoplasms | Major topic |
| Humans | |
| T-Lymphocytes | |
| CRISPR-Cas Systems | |
| Gene Editing | |
| Neoplasm Recurrence, Local | |
| Immunotherapy, Adoptive |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 20220309 | the Young Talent fund of the University Association for Science and Technology in Shaanxi, China | PubMed |
Source PubMed
References145
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35918210 | Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment. | Cytokine Growth Factor Rev | 2022 | https://conductscience.org/library/papers/35918210 | PubMed |
| 2 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 3 | 25939063 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. | Nat Med | 2015 | https://conductscience.org/library/papers/25939063 | PubMed |
| 4 | 34072068 | CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34072068 | PubMed |
| 5 | 33272898 | Memory CD8+ T cell responses to cancer. | Semin Immunol | 2020 | https://conductscience.org/library/papers/33272898 | PubMed |
| 6 | 27745970 | L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. | Cell | 2016 | https://conductscience.org/library/papers/27745970 | PubMed |
| 7 | 30814732 | NR4A transcription factors limit CAR T cell function in solid tumours. | Nature | 2019 | https://conductscience.org/library/papers/30814732 | PubMed |
| 8 | 32364534 | Replacing CAR-T cell resistance with persistence by changing a single residue. | J Clin Invest | 2020 | https://conductscience.org/library/papers/32364534 | PubMed |
| 9 | 33312759 | Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. | Oncoimmunology | 2020 | https://conductscience.org/library/papers/33312759 | PubMed |
| 10 | 35314843 | PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35314843 | PubMed |
| 11 | 36755094 | TET2 guards against unchecked BATF3-induced CAR T cell expansion. | Nature | 2023 | https://conductscience.org/library/papers/36755094 | PubMed |
| 12 | 28648661 | De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. | Cell | 2017 | https://conductscience.org/library/papers/28648661 | PubMed |
| 13 | 35110735 | Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. | Nature | 2022 | https://conductscience.org/library/papers/35110735 | PubMed |
| 14 | 35503659 | CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. | J Clin Invest | 2022 | https://conductscience.org/library/papers/35503659 | PubMed |
| 15 | 34861191 | An NK-like CAR T cell transition in CAR T cell dysfunction. | Cell | 2021 | https://conductscience.org/library/papers/34861191 | PubMed |
| 16 | 32413572 | CRISPR screen in mechanism and target discovery for cancer immunotherapy. | Biochim Biophys Acta Rev Cancer | 2020 | https://conductscience.org/library/papers/32413572 | PubMed |
| 17 | 30158648 | Cas9 immunity creates challenges for CRISPR gene editing therapies. | Nat Commun | 2018 | https://conductscience.org/library/papers/30158648 | PubMed |
| 18 | 34794959 | PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34794959 | PubMed |
| 19 | 24336571 | Genome-scale CRISPR-Cas9 knockout screening in human cells. | Science | 2014 | https://conductscience.org/library/papers/24336571 | PubMed |
| 20 | 30684591 | CRISPR-Cas9 for cancer therapy: Opportunities and challenges. | Cancer Lett | 2019 | https://conductscience.org/library/papers/30684591 | PubMed |
Cited by47
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42819907 | Adoptive T Cell therapy for cancer and autoimmune disease: current advances, challenges, and future directions. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42819907 | PubMed |
| 42812538 | The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment. | Front Mol Med | 2026 | https://conductscience.org/library/papers/42812538 | PubMed |
| 42749951 | From scissors to editors: how the evolution of precision is redefining therapeutic genome editing. | Mol Genet Genomics | 2026 | https://conductscience.org/library/papers/42749951 | PubMed |
| 42662940 | The landscape and trajectory of global CRISPR therapeutics. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42662940 | PubMed |
| 42610144 | AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery. | Iran J Basic Med Sci | 2026 | https://conductscience.org/library/papers/42610144 | PubMed |
| 42454036 | Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology. | Front Immunol | 2026 | https://conductscience.org/library/papers/42454036 | PubMed |
| 42245657 | PTPN6/SHP-1 in autoimmune disease: immune tolerance, regulatory mechanisms, and therapeutic targeting. | Front Immunol | 2026 | https://conductscience.org/library/papers/42245657 | PubMed |
| 42220535 | Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions. | Front Immunol | 2026 | https://conductscience.org/library/papers/42220535 | PubMed |
| 41586193 | Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer. | Iran J Basic Med Sci | 2025 | https://conductscience.org/library/papers/41586193 | PubMed |
| 41428622 | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turk J Haematol | 2026 | https://conductscience.org/library/papers/41428622 | PubMed |
| 41409286 | The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41409286 | PubMed |
| 41404500 | Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential. | Mol Ther Nucleic Acids | 2025 | https://conductscience.org/library/papers/41404500 | PubMed |
| 41240134 | CRISPR-Cas9 in leukemia immunotherapy: precision engineering of CAR-T cells and tumor-microenvironment modulation. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/41240134 | PubMed |
| 41179303 | Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges. | Oncol Res | 2025 | https://conductscience.org/library/papers/41179303 | PubMed |
| 41097713 | A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097713 | PubMed |
| 41096852 | Special Issue "The Promising Future of CAR-Based Therapies: A Matter of Molecular Details". | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41096852 | PubMed |
| 40810970 | Adoptive T-Cell Therapy in Sarcomas. | Curr Oncol Rep | 2025 | https://conductscience.org/library/papers/40810970 | PubMed |
| 40781676 | Cellular senescence in cancer: from mechanism paradoxes to precision therapeutics. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40781676 | PubMed |
| 40722155 | Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/40722155 | PubMed |
| 40699667 | Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/40699667 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37569693
GET https://conductscience.org/api/papers/v1/37569693/references?page=2